Trendlines raises $3.2m fund for distribution of new surgical instrument

The new instrument will be used for abdominal operations.

Singapore-listed medical investor The Trendlines Group has won a $3.2m funding to start marketing and distributing a new surgical instrument that will be used in abdominal operations.

The funding is directed to Trendlines' medical portfolio company Gordian Surgical, which developed TroClose1200. Gordian announced that it has already secured Food and Drug Administration regulatory clearance for the new instrument.

The development is to give surgeons “two-in-one” functionality: the device acts both as a trocar, through which surgical instruments enter the abdomen, and a device to close internal incisions made during surgery.

“Receiving FDA clearance is a huge milestone in Gordian’s strategic roadmap. The recent investment, led by B. Braun, allows us to move rapidly towards commercialization of our device in the U.S., Europe and other markets," Gordian Surgical CEO Zvi Pe’er said.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia